OU researcher to study CAR T-Cell and opaganib combination in clinical trials for ultra-high-risk multiple myeloma
October 19, 2026
October 19, 2026
NORMAN, Oklahoma, Oct. 19 -- The University of Oklahoma posted the following news:
* * *
OU researcher to study CAR T-Cell and opaganib combination in clinical trials for ultra-high-risk multiple myeloma
*
OKLAHOMA CITY - Patients with ultra-high-risk multiple myeloma, an aggressive form of blood cancer, often respond poorly to standard treatments, including bone marrow transplant. A University of Oklahoma physician-researcher recently received . . .
* * *
OU researcher to study CAR T-Cell and opaganib combination in clinical trials for ultra-high-risk multiple myeloma
*
OKLAHOMA CITY - Patients with ultra-high-risk multiple myeloma, an aggressive form of blood cancer, often respond poorly to standard treatments, including bone marrow transplant. A University of Oklahoma physician-researcher recently received . . .